Table 2. Grade 3 and higher toxicities between the combined regimen versus chemotherapy or EGFR-TKIs monotherapy.
| Subgroup | Included trials | Odds Ratio (95% CI) | P | Heterogeneity test I2 (%) P | |
|---|---|---|---|---|---|
| Hematologic | |||||
| Leukopenia | 10 | 1.34 [1.05, 1.72] | 0.02 | 50 | 0.03 |
| Neutropenia | 15 | 1.47 [1.02, 2.11] | 0.04 | 68 | < 0.01 |
| Febrile neutropenia | 5 | 4.95 [2.45, 9.99] | < 0.01 | 0 | 0.45 |
| Thrombocytopenia | 10 | 1.25 [1.00, 1.57] | 0.05 | 0 | 0.44 |
| Anemia | 14 | 1.51 [1.21, 1.89] | < 0.01 | 0 | 0.8 |
| Non-hematologic | |||||
| Rash | 14 | 3.84 [2.07, 7.14] | < 0.01 | 58 | < 0.01 |
| Anorexia | 9 | 1.65 [0.99, 2.75] | 0.06 | 0 | 0.57 |
| Fatigue | 12 | 1.53 [1.12, 2.08] | < 0.01 | 47 | 0.04 |
| Vomiting | 10 | 1.14 [0.84, 1.54] | 0.39 | 6 | 0.38 |
| Nausea | 10 | 1.09 [0.79, 1.50] | 0.61 | 0 | 0.52 |
| Diarrhea | 14 | 3.28 [2.37, 4.54] | < 0.01 | 3 | 0.42 |
| Constipation | 4 | 1.00 [0.32, 3.16] | 0.99 | 0 | 0.54 |
| Dyspnea | 6 | 0.85 [0.60, 1.19] | 0.34 | 0 | 0.91 |